Pharmacological approaches to the therapy of Alzheimer's disease

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 9-10, 2006, Pages 30-34

  Gavrilova, S I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751556057     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Evans W., Mcleod H. Pharmacologenomics -drug disposition, drug targets and side effects. N. Engl. J. Med. 2003; 348 (6): 538-549.
2. Pericak-Vance M. A., Bebout J. L, Gaskell P. C. et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am. J. Hum. Genet. 1991; 48: 1034-1050.
3. Strittmatter W. J., Sounders A. M., Schmechel D. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA 1993; 90: 1977-1981.
4. Sanders A. M., Strittmatter W. J., Schmechel D. et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
5. Van Duijn C. M., de Knijff P., Cruts M. et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat. Genet. 1994; 7: 74-78.
6. Corder E. H., Sounders A. M., Strittmatter W. J. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
7. Van Duijn C. M., de Knijff P., Wehnert A. et al. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann. Neurol. 1995; 37: 605-610.
8. Ma J., Yee A., Brewer H. B. et al. Amyloid-associated proteins alpha-1 antichymotrypsin and apolipoprotein E promote assembly of Alzheimer's beta-protein into filaments. Nature 1994; 372: 92-94.
9. Bales K. R., Verina T., Dodel R. C. et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997; 17: 263-264.
10. Pericak-Vance M. A., Hainess J. L. Genetic susceptibility to Alzheimer's disease. Trends Genet. 1995; 11: 504-508.
11. Wahlund L. O., Julin P., Lannfelt L. et al. Inheritance of the ApoE epsilon 4 allele increase the rate of brain atrophy in dementia patients. Dement. Geriatr. Cogn. Disord. 1999; 10: 262-268.
12. Wallin A. K., Gustafson L., Sjogren M. et al. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement. Geriatr. Cogn. Disord. 2004; 18: 197-206.
13. Farrer L. A., Cupples L. A., Haines J. L. et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. A meta-analysis. APOE and Alzheimer's Disease Meta-Analysis Consortium. J. A. M. A. 1997; 278: 1349-1356.
14. Wilson R. S., Schneider J. A., Barnes L. L. et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch. Neurol. 2002; 59: 1154-1160.
15. Bondi M. W., Salmon D. P., Monsch A. U. et al. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology 1995; 45: 2203-2206.
16. Mayeux R., Small S. A., Tang M. et al. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein E. Neurobiol. Aging 2001; 22: 683-689.
17. O'Hara R., Yesavage J. A., Kraemer H. C. et al. The APOE epsilon 4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J. Am. Geriatr. Soc. 1998; 46: 1493-1498.
18. Schachter A. S., Davis K. L. Alzheimer's disease. Dialog. Clin. Neurosci. 2000; 2 (2): 91-100.
19. Sjogren M., Hesse C., Busun H. et al. Tacrine and rate of progression in Alzheimer's disease relation to ApoE allele genotype. J. Neural Transm. 2001; 108: 451-458.
20. Farlow M., Lane R., Kudaravalli S., He Y. Differential qualitative responses to rivastigmine in ApoE ε4 carriers and noncarriers. J. Pharmacogenom. 2004; 4: 332-335.
21. Almkvist O., Darreh-Shori T., Stefanova E. et al. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur. J. Neurol. 2004; 11: 253-261.
22. Aerssens J., Raeymaekers P., Lilienfeld S. et al. APOE genotype: no influence on galantamine treatment efficacy nor rate of de cline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2001; 12: 69-77.
23. Courtney C., Farrell D., Gray R. et al. AD 2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): randomised double-blind trial. Lancet 2004; 363: 2105-2115.
24. Bizzarro A., Marra C., Acciarri A. et al. Apolipoprotein Eε4 allele differentiates the clinical response to donepezil in Alzheimer's disease. J. Dementia 2005; 20: 254-260.
25. Windisch M., Gschanes A., Hutter-Paier B. Neurotrophic activities and therapeutic experience with brain derived peptide preparation. J. Neural Transm. 1998; suppl. 53: 289-298.